MarginsXMarginsX
Home › Markets › Health Care › IBIO

iBio Inc. (IBIO)

IBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.7067
-3.42% on the day
Market cap
$49.8M
Nano cap
Revenue · 2026
$100K
-75.0% on 2025
Net income · 2026
-$33.0M
-33044.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1420720/000142072026000020/0001420720-26-000020-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerIBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001420720
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2026

LineValue
Revenue$100K
Net income-$33.0M
Operating income-$35.1M
Net margin-33044.0%
Operating margin-35141.0%
Revenue growth-75.0%
Cash$56.4M
Total assets$99.1M
P/E (computed)Net income was not positive
P/S (computed)497.9×

Warning signs

Cash runway
20.2 months
$45.4M cash at September 30, 2026
Share count, 1 year
+213.3%
2025-11-10 to 2026-11-10 · +4914.5% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$98K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Despite this liquidity position, the history of significant losses, the negative cash flow from operations, and the dependence by us on our ability to obtain additional financing to fund our operations raised substantial doubt about our ability to continue as a going concern."
10-Q 2026-11-10
Cash and burn$45.4M cash; operating cash flow -$6.7M a quarter.Report 2026-09-30
Shares outstanding70,455,809 (2026-11-10); 22,487,308 a year earlier; 28,100,733 three years earlier. 3y figure adjusted for splits (1-for-20 overall).Cover page 2026-11-10
Reverse splits, 3 years1; latest 1-for-20 on 2023-11-29Source 2023-11-29
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25 filed25 2025-03-03
AuditorGrassi & Co., CPAs, P.C., Jericho, New York, United StatesPCAOB Form AP 2026-09-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $98K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
$1.1M-$7.6M-$9.4M$45.4MNo debt tags$1.1M10-Q 2026-11-10
Q4 2026
2026-06-30
$0-$10.6M-$6.2M$56.4MNo debt tags$100K10-K 2026-08-28
Q3 2026
2026-03-31
$0-$7.7M-$6.1M$47.6MNo debt tags$300K10-Q 2026-05-12
Q2 2026
2025-12-31
$0-$9.0M-$5.2M$28.7MNo debt tags$300K10-Q 2026-02-10
Q1 2026
2025-09-30
$100K-$5.7M-$5.7M$28.1M$706K$500K10-Q 2026-11-10
Q4 2025
2025-06-30
$200K-$5.2M-$4.6M$8.6M$766K$400K10-K 2026-08-28
Q3 2025
2025-03-31
$0-$4.9M-$3.1M$5.0M$824K$375K10-Q 2025-05-02
Q2 2025
2024-12-31
$200K-$4.4M-$3.9M$7.0M$237K$375K10-Q 2026-02-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-04-29
Latest annual report10-K2026-08-28
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-09-04

Source: SEC EDGAR submissions feed, 911 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.4%
1 month-6.4%
3 months-47.9%
Year to date-62.2%
1 year-36.5%
From 52-week high-76.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CTORCitius Oncology Inc.$0.5350-6.76%$49.7M
RFLRafael Holdings Inc.$0.9701-9.34%$50.6M
MREOMereo BioPharma Group plc$0.3050-0.81%$48.7M
QUCYQuantum Cyber N.V.$0.5850-7.58%$51.0M
HOWLWerewolf Therapeutics Inc.$0.9908+1.07%$48.2M
SDEVStablecoin Development Corporation$0.7055-9.55%$51.6M
APLMApollomics Inc.$17.84+0.91%$51.7M
CLNNClene Inc.$3.66-6.63%$52.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier